Chapin Davis Inc. Buys Shares of 17,000 LivaNova PLC (NASDAQ:LIVN)

Chapin Davis Inc. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the 1st quarter, HoldingsChannel reports. The firm purchased 17,000 shares of the company’s stock, valued at approximately $668,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LIVN. Rhumbline Advisers increased its position in shares of LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after buying an additional 899 shares during the period. Principal Financial Group Inc. grew its holdings in LivaNova by 2.6% during the 4th quarter. Principal Financial Group Inc. now owns 175,878 shares of the company’s stock worth $8,145,000 after acquiring an additional 4,476 shares during the period. New York State Common Retirement Fund grew its holdings in LivaNova by 122.8% during the 4th quarter. New York State Common Retirement Fund now owns 37,557 shares of the company’s stock worth $1,739,000 after acquiring an additional 20,699 shares during the period. Handelsbanken Fonder AB raised its position in shares of LivaNova by 12.1% in the 4th quarter. Handelsbanken Fonder AB now owns 17,637 shares of the company’s stock worth $817,000 after acquiring an additional 1,900 shares in the last quarter. Finally, Amalgamated Bank lifted its stake in shares of LivaNova by 3.0% in the 4th quarter. Amalgamated Bank now owns 24,900 shares of the company’s stock valued at $1,153,000 after purchasing an additional 729 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Up 0.8%

LivaNova stock opened at $45.51 on Monday. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -11.13 and a beta of 0.90. The firm’s fifty day moving average price is $41.63 and its two-hundred day moving average price is $43.57. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LIVN shares. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. The Goldman Sachs Group cut their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Stifel Nicolaus lowered their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Finally, Wall Street Zen downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Buy” and an average target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.